In light of recent WHO classification update for glioma, how would your treatment volumes and dose prescription change for a non-enhancing molecular glioblastoma?

I would argue that the CTV for a molecularly defined IDH-wt tumor without radiographic hallmarks of contrast enhancement should be considered differently than for those of a more "classic" radiographic/histologic GBM (i.e., with mitoses, endothelial proliferation, atypia, necrosis). It's a different...